#1 Clinical Trials Search in Europe

Codeine Phosphate

This article examines several clinical trials investigating the use of codeine phosphate, a commonly prescribed opioid medication, for treating various medical conditions. The studies explore codeine’s effectiveness, safety, and potential applications in areas such as pain management, cough suppression, and gastrointestinal motility disorders. By analyzing these trials, we can gain insights into the drug’s benefits, limitations, and optimal usage in clinical practice.

Table of Contents

What is Codeine Phosphate?

Codeine phosphate is a medication that belongs to a class of drugs called opioids. It is used primarily for pain relief and as a cough suppressant. Codeine phosphate is derived from the opium poppy plant and is considered a milder opioid compared to stronger drugs like morphine[1].

This medication is also known by several other names, including:

  • Codeine
  • Bronchodine[2]

Uses and Conditions Treated

Codeine phosphate is prescribed for various medical conditions, including:

  • Pain relief: It is used to treat mild to moderate pain, such as that associated with arthroscopic meniscus surgery[3].
  • Cough suppression: Codeine phosphate is effective in treating coughs, especially when combined with other medications like guaifenesin[1].
  • Temporomandibular disorders (TMDs): These are conditions affecting the jaw joint and surrounding muscles. Codeine phosphate, in combination with other drugs, may be used to manage pain associated with TMDs[4].
  • Sciatica: This is a condition characterized by pain radiating along the sciatic nerve. Codeine phosphate may be used in combination with other medications to treat acute sciatica[5].
  • Post-operative pain management: It can be used to manage pain after surgeries, such as cleft palate repair in infants[6].

How Codeine Phosphate Works

Codeine phosphate works by binding to specific receptors in the brain and nervous system called mu-opioid receptors (MOR). This action helps to reduce the perception of pain and suppress cough reflexes. When codeine enters the body, it is converted to morphine, which is its active form[1].

Key points about how codeine phosphate works:

  • It takes effect within about 20 minutes after ingestion.
  • The peak effect is reached within 2 hours.
  • The analgesic (pain-relieving) action typically lasts for about 4 hours[1].

Dosage and Administration

The dosage of codeine phosphate can vary depending on the specific condition being treated and the individual patient. Some common dosages observed in clinical trials include:

  • 30 mg every 4-6 hours for pain relief[1]
  • 15 mg three times daily when used in combination with other pain medications[7]
  • 60 mg for studying effects on esophageal motility[8]

It’s important to note that codeine phosphate should only be taken as prescribed by a healthcare professional. The dosage and frequency may be adjusted based on the patient’s response and any side effects experienced.

Side Effects and Safety

Like all medications, codeine phosphate can cause side effects. Some common side effects may include:

  • Drowsiness
  • Nausea
  • Constipation
  • Dizziness
  • Respiratory depression (slowed breathing)[2]

Codeine phosphate can be habit-forming and may lead to dependence if used for prolonged periods or in high doses. It’s important to use this medication exactly as prescribed and to discuss any concerns with your healthcare provider.

Combinations with Other Medications

Codeine phosphate is often combined with other medications to enhance its effectiveness or to treat multiple symptoms. Some common combinations include:

  • Codeine phosphate with guaifenesin: This combination is used for cough suppression and as an expectorant[1].
  • Codeine phosphate with paracetamol (acetaminophen): This combination provides enhanced pain relief[9].
  • Codeine phosphate with naproxen sodium: This combination is used for pain relief in conditions like temporomandibular disorders[4].
  • Codeine phosphate with diclofenac: This combination is being studied for the treatment of acute sciatica[5].

Research and Clinical Trials

Ongoing research and clinical trials are exploring various aspects of codeine phosphate use, including:

  • Its effectiveness in treating acute sciatica when combined with other medications[5].
  • The impact of codeine on esophageal and pharyngeal motility (movement of the esophagus and throat)[8].
  • Its effects on colonic motor patterns (movement patterns in the large intestine)[2].
  • The use of codeine phosphate in managing post-operative pain in infants after cleft palate repair[6].

These studies aim to improve our understanding of how codeine phosphate works and to optimize its use in various medical conditions.

Aspect Details
Conditions Studied Cough, post-operative pain, opioid-induced constipation, acute sciatica, temporomandibular disorders, gastric motility
Formulations Extended-release tablets, immediate-release tablets, combination products (with guaifenesin, paracetamol)
Comparators Placebos, naproxen, diclofenac, morphine
Primary Outcomes Pain reduction, changes in gastric motility, bioavailability, pharmacokinetics, cough suppression efficacy
Safety Assessments Adverse events, vital signs, gastrointestinal function
Special Populations Infants (cleft palate repair), healthy volunteers (gastric motility study)
Study Designs Randomized controlled trials, crossover studies, bioequivalence studies

FAQ

  • What conditions are being studied with codeine phosphate in these clinical trials? The clinical trials are investigating codeine phosphate for various conditions including cough, pain management after cleft palate repair in infants, opioid-induced constipation, acute sciatica, temporomandibular disorders, and gastric motility disorders.
  • How is codeine phosphate being compared to other treatments in these studies? Codeine phosphate is being compared to placebos, other pain medications like naproxen and diclofenac, and different formulations (e.g., extended-release vs. immediate-release). Some studies also examine codeine in combination with other drugs like guaifenesin or paracetamol.
  • What are some of the primary outcomes being measured in these trials? Primary outcomes include pain reduction (measured by visual analog scales), changes in gastric motility, bioavailability and pharmacokinetics of different formulations, efficacy in reducing cough, and safety assessments including adverse events.
  • Are there any studies looking at codeine's effects on specific patient populations? Yes, one study is specifically examining codeine phosphate's analgesic effects in infants undergoing cleft palate repair surgery. Another study is investigating its use in healthy volunteers to assess effects on gastric motility.
  • What are some potential side effects or safety concerns being monitored in these trials? The trials are monitoring for common opioid-related side effects such as constipation, nausea, and drowsiness. They are also assessing the overall safety profile, including any serious adverse events, changes in vital signs, and potential impacts on gastrointestinal function.

Ongoing Clinical Trials on Codeine Phosphate

  • Study of Pembrolizumab and MK-2870 for Patients with Metastatic Squamous Non-small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Czechia France Germany Hungary Ireland +4

  • Study on MK-2870, Pembrolizumab, and Chemotherapy for Patients with Advanced Gastroesophageal Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Norway

  • Study of Pembrolizumab, Vibostolimab, and Chemotherapy for Patients with Newly Diagnosed Resectable Stage II-IIIB Non-Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated drugs:
    Germany Greece Hungary Italy Poland Spain

  • Study on the Safety and Dosage of GD2IL18CART for Patients with Relapsed or Refractory GD2 Positive Solid Cancers

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark France Germany Greece +10

  • Study on the Safety and Effectiveness of mRNA-3927 for Patients with Propionic Acidemia

    Recruiting

    2 1 1 1
    Investigated drugs:
    France Italy The Netherlands Spain

  • Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +9

  • Study of Lenvatinib, Pembrolizumab, and Chemotherapy Combination for Patients with Advanced Esophageal Cancer Previously Treated with PD-1/PD-L1 Therapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Germany Italy Norway

  • Study of MK-2870 and Chemotherapy for Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Poland Spain Sweden

  • Study on the Safety and Effectiveness of MK-2870 Alone or with Other Drugs for Patients with Colorectal, Pancreatic, and Biliary Tract Cancers

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Spain

Glossary

  • Bioavailability: The proportion of a drug or substance which enters the circulation when introduced into the body and so is able to have an active effect.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Visual Analog Scale (VAS): A measurement tool used to help patients rate the intensity of certain sensations and feelings, such as pain. It is usually a straight line with one end meaning no pain and the other end meaning the worst pain imaginable.
  • Placebo: A substance or treatment with no active therapeutic effect, used as a control in testing new drugs.
  • Opioid: A class of drugs that includes the illegal drug heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescription, such as oxycodone, hydrocodone, codeine, and morphine.
  • Extended-release: A formulation of a drug designed to release the active ingredient slowly over time, allowing for less frequent dosing.
  • Immediate-release: A formulation of a drug designed to release the active ingredient quickly after administration.
  • Gastric motility: The movement of food from the mouth through the esophagus and stomach, into the small intestine.
  • Temporomandibular disorder: A condition affecting the jaw joints and surrounding muscles, often causing pain and difficulty in jaw movement.
  • Sciatica: Pain that radiates along the path of the sciatic nerve, which branches from your lower back through your hips and buttocks and down each leg.

References

  1. https://clinicaltrials.gov/study/NCT02572375
  2. https://clinicaltrials.gov/study/NCT05770960
  3. https://clinicaltrials.gov/study/NCT01952652
  4. https://clinicaltrials.gov/study/NCT04066426
  5. https://clinicaltrials.gov/study/NCT05626140
  6. https://clinicaltrials.gov/study/NCT00386269
  7. https://clinicaltrials.gov/study/NCT00147355
  8. https://clinicaltrials.gov/study/NCT03784105
  9. https://clinicaltrials.gov/study/NCT02902666